#USA #Bethesda #ADHD treatment #HarmonEyes #iFocus Health

HarmonEyes Acquires iFocus Health for Enhanced ADHD Treatment

In a significant stride towards revolutionizing ADHD treatment, HarmonEyes, known for its innovations in AI-driven eye-tracking software, has announced its acquisition of iFocus Health. This merger introduces an advanced solution for managing ADHD medication, leveraging eye-tracking technology to provide real-time insights into treatment efficacy.

Eye-Tracking Technology: A Game Changer in ADHD Management

The iFocus Health platform addresses a critical challenge faced in ADHD care—the absence of reliable biomarkers for assessing treatment progress. Traditionally, adjustments in medication have been predominantly reliant on subjective methods, including patients' self-reports and behavioral checklists. This new acquisition transforms that paradigm. By tracking eye movement during everyday activities such as reading, iFocus offers clinicians objective, actionable data that bolsters their decision-making processes regarding ADHD treatment.

CEO and co-founder of iFocus Health, Adi Diner, emphasized the significance of this technology, stating, "ADHD isn't just about distraction; it's about underperformance in a world that demands focus." The integration with HarmonEyes aims to expand this capability to reach millions, providing a personalized approach to ADHD that moves away from traditional trial-and-error methods towards a more efficient, metrics-based treatment model.

Rebranding and Broader Mission

Now recognized as HarmonEyes Focus, the technology acquired from iFocus becomes a crucial element of HarmonEyes' larger mission to redefine human performance through eye movement analysis. The merger envisages a symbiotic relationship where HarmonEyes' AI capabilities bolster the measurement of ADHD treatment outcomes. Whether in healthcare settings, educational environments, or daily life scenarios, the end goal is to enhance understanding of cognitive and emotional responses, thereby optimizing individual performance levels.

According to the CDC, around 6 million children and approximately 16 million adults in the United States are diagnosed with ADHD. Despite the vast number of affected individuals, many still rely on outdated methods for medication management. HarmonEyes Focus promises a transformative shift by providing real-time, data-driven insights that enhance clinicians' confidence in fine-tuning treatment plans based on patients' actual progress.

Strategic Vision and Future Potential

Adam Gross, CEO and co-founder of HarmonEyes, highlighted the acquisition as a pivotal aspect of their strategy to establish the first foundational model for eye-tracking geared towards understanding human states. He remarked, "iFocus brings a proven and relevant use case that aligns perfectly with our broader vision."

The integration of iFocus Health's objective assessment methodology with HarmonEyes' advanced eye-tracking technology paves the way for future adaptations that could support various neurodevelopmental conditions. There remains significant potential to apply these advancements in optimizing performance across educational settings and workplaces, as well as enhancing recovery in clinical environments.

Conclusion

The acquisition symbolizes HarmonEyes' commitment to integrating objective metrics into crucial decision-making processes, ultimately fostering better health outcomes. This combination of technologies holds promise not just for addressing ADHD, but for advancing our understanding of neurodiversity in various life aspects. For more information about HarmonEyes and its revolutionary eye-tracking solutions, visit www.harmoneyes.com.

About HarmonEyes

HarmonEyes represents the forefront of eye-tracking technology, operating as the world's only open, AI-powered platform that interprets cognitive, emotional, and physical states based solely on eye movement. Compatible with any camera-based device, HarmonEyes facilitates the analysis of eye-tracking data while offering a scalable solution for diverse applications across critical industries, including healthcare and high-performance sectors. Backed by an extensive database and over 60 years of experience, HarmonEyes continues to partner with global leaders in technology, aviation, and healthcare.

For any media inquiries, please contact Lightspeed PR at [email protected].